ELISA/assay

TNF alpha Neutralization Rate/Adalimumab ELISA Assay Kit

R222

1 Microplate/7 determinations

TNF alpha Neutralization Rate/Adalimumab ELISA Assay Kit

Tumour necrosis factor (TNFα) is a signalling substance of the immune system which can cause, among other things, the formation of inflammatory mediators in cells. In inflammatory diseases such as rheumatoid arthritis, there is overproduction of TNFα, which can be inhibited by using therapeutic antibodies.

RecoveryELISA is performed in a 96-well microplate. The wells of the microplate are pre-coated with a specific capture antibody against human TNFα that binds free TNFα from the patient sample. There occurs a simultaneous incubation of the TNFα levels (with and without the addition of Adalimumab) of the samples and of the detection conjugate (peroxidase conjugate of an anti-TNFα antibody). Incubation takes place over 16 to 22 hours at 2 to 8°C. After washing, the colour substrate TMB (tetramethylbenzidine) is added to the wells. After incubation the enzymatic colour reaction is stopped using a sulphuric acid solution. A colour change from blue to yellow occurs that is optically detected. Using a wavelength of 450 nm (reference value 620 nm), the optical density (OD) of the reaction product is measured with a suitable microplate reader. With the aid of the two calibrations to be performed, an evaluation procedure can be carried out to determine the concentrations of free TNFα and Adalimumab in the patient samples using the measured OD values. Determination of the therapeutic antibody is based on the principle that the presence of Adalimumab in patient samples leads to a systematic reduction in the recovery of TNFα.

ELISA

Assay Kits

Immunology

1 Microplate/7 determinations

TNF alpha adalimumab

Adalimumab: 0.7 ug/mL; TNF alpha: 4ng/ml

Adalimumab: 0.7 – 30 ug/mL; TNF alpha in sample without Adalimumab: 4-400ng/ml;TNF alpha in sample with Adalimumab: 4-160ng/ml

60uL

Serum

overnight

Human

RUO

wet

2-8C